Molecular Determinants of Altered Ca 2+ Handling in Human Chronic Atrial Fibrillation
- 15 August 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Cell Metabolism
- Vol. 114 (7), 670-680
- https://doi.org/10.1161/circulationaha.106.636845
Abstract
Background— Abnormal Ca 2+ handling may contribute to impaired atrial contractility and arrhythmogenesis in human chronic atrial fibrillation (cAF). Here, we assessed the phosphorylation levels of key proteins involved in altered Ca 2+ handling and contractility in cAF patients. Methods and Results— Total and phosphorylation levels of Ca 2+ -handling and myofilament proteins were analyzed by Western blotting in right atrial appendages of 49 patients in sinus rhythm and 52 cAF patients. We found a higher total activity of type 1 (PP1) and type 2A phosphatases in cAF, which was associated with inhomogeneous changes of protein phosphorylation in the cellular compartments, ie, lower protein kinase A (PKA) phosphorylation of myosin binding protein-C (Ser-282 site) at the thick myofilaments but preserved PKA phosphorylation of troponin I at the thin myofilaments and enhanced PKA (Ser-16 site) and Ca 2+ -calmodulin protein kinase (Thr-17 site) phosphorylation of phospholamban. PP1 activity at sarcoplasmic reticulum is controlled by inhibitor-1 (I-1), which blocks PP1 in its PKA-phosphorylated form only. In cAF, the ratio of Thr-35–phosphorylated to total I-1 was 10-fold higher, which suggests that the enhanced phosphorylation of phospholamban may result from a stronger PP1 inhibition by PKA-hyperphosphorylated (activated) I-1. Conclusions— Altered Ca 2+ handling in cAF is associated with impaired phosphorylation of myosin binding protein-C, which may contribute to the contractile dysfunction after cardioversion. The hyperphosphorylation of phospholamban probably results from enhanced inhibition of sarcoplasmic PP1 by hyperphosphorylated I-1 and may reinforce the leakiness of ryanodine channels in cAF. Restoration of sarcoplasmic reticulum–associated PP1 function may represent a new therapeutic option for treatment of atrial fibrillation.Keywords
This publication has 45 references indexed in Scilit:
- Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusionJCI Insight, 2006
- Reprogramming of the Human Atrial Transcriptome in Permanent Atrial FibrillationCirculation Research, 2005
- Down-regulation of sarcolipin mRNA expression in chronic atrial fibrillationEuropean Journal of Clinical Investigation, 2004
- Overexpression of the Catalytic Subunit of Protein Phosphatase 2A Impairs Cardiac FunctionPublished by Elsevier BV ,2004
- Troponin I Isoform Expression in Human and Experimental Atrial FibrillationCirculation, 2004
- Constitutive Cardiac Overexpression of Sarcoplasmic/Endoplasmic Reticulum Ca 2+ -ATPase Delays Myocardial Failure After Myocardial Infarction in Rats at a Cost of Increased Acute ArrhythmiasCirculation, 2004
- Phospholamban: a crucial regulator of cardiac contractilityNature Reviews Molecular Cell Biology, 2003
- Evidence for protein phosphatase inhibitor‐1 playing an amplifier role in β‐adrenergic signaling in cardiac myocytesThe FASEB Journal, 2003
- Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors.Hypertension, 1993
- Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholambanEuropean Journal of Biochemistry, 1991